MOTS-c vs Elamipretide: evidence, safety and FDA status
PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated (how dates work) · Not reviewed by a medical professional
The short answer
Both target mitochondria, but they sit in very different places. Elamipretide (SS-31) is FDA-approved as Forzinity for Barth syndrome, a rare genetic disease. MOTS-c is an unapproved research peptide with no published human safety data.
Key differences
Elamipretide’s Barth syndrome trial (12 people) missed both main measures in its blinded phase; improvements appeared later in an open-label extension.
MOTS-c has no placebo-controlled human trial, published or registered; FDA found no human exposure data.
Elamipretide’s main safety concerns are injection-site and allergic reactions, and its human safety data are very limited.
Both are marketed online for energy, aging and exercise; neither is approved or proven for those uses.
MOTS-c is a 16-amino-acid peptide studied as a mitochondrial signal. Its metabolic research is frequently discussed alongside exercise and aging.
Elamipretide targets mitochondrial biology. Its approved product, Forzinity, has a specific Barth syndrome indication rather than a general anti-aging use.
Human evidence
No human studies in our sources; animal and lab studies only
No randomized trials · crossover trial + open extension
Human safety data
None. Unapproved mitochondrial peptide. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown.
FDA label. Recently approved mitochondria-targeting drug for Barth syndrome; human safety data are very limited, and injection-site and allergic reactions are the main concerns.
Boxed warning
No FDA label to carry one
None on the FDA label
Serious risks
Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Allergic reactions, from skin rashes and cough to serious reactions needing emergency care, appearing minutes to months after starting
Benzyl alcohol toxicity (gasping syndrome) in newborns
Conditions flagged
None flagged, because there is too little human safety data to assess
Each row comes from the MOTS-c and Elamipretide profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
The human studies
MOTS-c
No human studies in our sources. See the MOTS-c profile for the animal and lab research.
Elamipretide
TAZPOWER (2021)
Human crossover trial + open extension · 12 participants with Barth syndrome in the blinded phase.
Neither primary endpoint—six-minute walking distance or symptom score—was met in the blinded phase. Improvements appeared in the extension, with eight participants reaching 36 weeks.
Limitation: An uncontrolled extension is less reliable for attributing benefit. Read the later FDA decision separately: accelerated approval used knee-muscle strength and requires confirmation of clinical benefit.
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Bottom line
An approval for one rare disease does not extend to general energy or longevity use, and MOTS-c’s case rests on cell and animal studies.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Plain-English summaries of new peptide studies, regulatory news and notable price changes from the sellers we track. No dosing advice. Unsubscribe anytime.
Peps